Table 1. Number of printed and violative antidepressant advertisements in the Swedish Medical Journal 1994–2003.
| Antidepressant ads | Ads in violation of code | ||||
| Product | Company | Unique ads (n = 124) | Total ads(n = 722) | Unique ads(n = 47) | Total ads (n = 247) |
| Citalopram (Cipramil) | Lundbeck | 25 (20.2%) | 171 (23.7%) | 12 (25.5%) | 88 (35.6%) |
| Escitalopram (Cipralex) | Lundbeck | 10 (8.1%) | 42 (5.8%) | 5 (10.6%) | 21 (8.5%) |
| Fluoxetine (Fontex) | Eli Lilly | 16 (12.9%) | 71 (9.8%) | 6 (12.8%) | 8 (3.2%) |
| Fluoxetine (Fluoxetine Selena) | Selena | 1 (0.8%) | 14 (1.9%) | 0 | 0 |
| Fluoxetine (Seroscand Fluoxetine) | Seroscand | 2 (1.6%) | 15 (2.1%) | 0 | 0 |
| Fluvoxamine (Fevarin) | Meda/Solvay | 2 (1.6%) | 3 (0.4%) | 1 (2.1%) | 1 (0.4%) |
| Mirtazapine (Remeron) | Organon | 10 (8.1%) | 70 (9.7%) | 3 (6.4%) | 44 (17.8%) |
| Moclobemide (Aurorix) | Roche | 4 (3.2%) | 21 (2.9%) | 0 | 0 |
| Nefazodon (Nefadar) | Bristol-Myers Squibb | 1 (0.8%) | 2 (0.3%) | 0 | 0 |
| Paroxetine (Seroxat) | Novo Nordisk/SmithKleinB | 25 (20.2%) | 73 (10.1%) | 10 (21.3%) | 21 (8.5%) |
| Reboxetine (Edronax) | Pharmacia & Upjohn | 1 (0.8%) | 5 (0.7%) | 0 | 0 |
| Sertraline (Zoloft) | Pfizer | 10 (8.1%) | 149 (20.6%) | 2 (4.3%) | 28 (11.3%) |
| Venlafaxine (Effexor) | Wyeth | 17 (13.7%) | 86 (11.9%) | 8 (17.0%) | 36 (14.6%) |